Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Am J Ophthalmol. 2022 Mar 7;241:262–271. doi: 10.1016/j.ajo.2022.02.023

Table 3.

Log Neutralizing Antibody Titers by Vector dose and Incident Uveitis at Baseline, Day 7, Day 90 and Year 1

Dose Low Medium High Higher

No Uveitis Uveitis with No Symptom No Uveitis Uveitis with No Symptom No Uveitis Uveitis with No Symptom No Uveitis Uveitis with No Symptom Uveitis with No Symptomatic

Visit Baseline mean
(SD)
2.28
(1.79)
4.31
(N/A)
1.23
(1.04)
1.90
(N/A)
0.70
(0.00)
4.31
(N/A)
0.70
(0.00)
0.70
(N/A)
1.45 (0.90)
N 8 1 8 1 2 1 2 1 4

mean 2.35 4.31 1.23 4.31 1.30 4.31 0.70 0.70 1.75 (1.24)
Day 7 (SD) (1.73) (N/A) (1.04) (N/A) (0.85) (N/A) (0.00) (N/A)
N 8 1 8 1 2 1 2 1 4

mean 2.51 4.31 1.23 4.31 1.30 4.31 0.70 3.11 3.71 (0.00)
Day 90 (SD) (1.81) (N/A) (0.88) (N/A) (0.85) (N/A) (0.00) (N/A)
N 7 1 8 1 2 1 1 1 1*

mean 2.59 1.47 4.31 1.00 4.31 1.30 0.70 3.11 (1.20)
Year 1 (SD) (1.72) (0.97) (N/A) (0/3) (N/A) (0.85) (N/A)
N 7 7 1 2 1 2 1 3
*

Two patients missed 90-day visits due to the Covid19 pandemic

One patient had year 1 follow-up with an outside physician, due to the Covid 19 pandemic, and the test wasn’t done